PRODUCT TYPES – Page 16

Occupational exposure limit breach during stability pull: containment CAPA and effectiveness checks

The initial identification of an OEL breach is typically characterized by several observable cues in both manufacturing and laboratory environments. Symptoms often manifest as chemical exposure indicators, abnormal employee health…

Finished product assay OOS during deviation triage meeting: how to defend specification setting and outlier handling during inspection

Detecting OOS results during final product assays is typically the first marker that an investigation is warranted. Symptoms may include:Click to read the full article.

Assay drift during shared facility campaign: risk assessment for patient safety

Identifying symptoms of assay drift is the first step in initiating an investigation. Common signals include:Click to read the full article.

Finished product dissolution failure during routine batch release: manufacturing vs lab root cause mapping and required evidence

The first sign of a potential dissolution failure often emerges during routine quality control (QC) testing. Symptoms can vary and may include:Click to read the full article.

Assay drift during stability pull: containment CAPA and effectiveness checks

Detecting assay drift early is crucial to maintaining product quality and regulatory compliance. Symptoms indicative of assay drift during stability pulls may include:Click to read the full article.

Finished product content uniformity OOS during complaint trending review: CAPA plan that inspectors accept (with effectiveness checks and due dates)

OOS results relating to finished product content uniformity may manifest through several symptoms or signals, which can indicate underlying issues in the manufacturing process:Click to read the full article.

Potency OOS during shared facility campaign: FDA/EMA investigation expectations

Symptoms related to potency OOS can manifest in various ways. Below are key signals that may indicate potential issues with product potency:Click to read the full article.

Finished product coating non-uniformity during CPV annual product review: how to build a deviation package that passes an inspection deep-dive

Addressing Finished Product Coating Non-Uniformity in CPV Annual Product Reviews In pharmaceutical manufacturing, the integrity and uniformity of product coatings are critical. Deviations observed during annual product reviews, particularly concerning…

Cross-contamination risk during stability pull: risk assessment for patient safety

The first step in addressing cross-contamination risks is recognizing the symptoms or signals that may indicate a problem during stability pulls. Symptoms can manifest in various forms, including:Click to read…

Finished product label mix-up deviation during PAI / FDA inspection readiness: manufacturing vs lab root cause mapping and required evidence

Symptoms of a potential finished product label mix-up can manifest in various forms, both on the manufacturing floor and in the quality control lab. Key indicators to monitor include:Click to…

Stability failure after equipment cleaning: risk assessment for patient safety

Before delving into the investigation process, it's vital to recognize the specific symptoms or signals that may indicate a stability failure. Common signals that should prompt immediate scrutiny include:Click to…

Finished product content uniformity OOS after packaging material change: FDA-compliant investigation flow and batch disposition decision tree

The manifestation of OOS findings regarding content uniformity can arise from various processes in manufacturing, especially during and after a packaging material change. Key symptoms on the production floor or…